Clinical study for predicting therapeutic effect of free circulating DNA in lung cancer radiotherapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027590

Enrollment

Unknown

Registered

2019-11-20

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Gold Standard:Clinical outcome

Index test:Free circulating DNA

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with lung cancer in the past three months do not limit the type of pathology.

Exclusion criteria

Exclusion criteria: Patients who have not received radiotherapy, patients who have interrupted radiotherapy, and patients who have received radiotherapy in addition to chemotherapy.

Design outcomes

Primary

Measure	Time frame
Free circulating DNA concentration;	—

Secondary

Measure	Time frame
Morphological characteristics of free circulating DNA;	—

Countries

China

Contacts

Public ContactZhangjinling

Linyi City People's Hospital

lysrmyykyk@163.com+86 0539-8071229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026